Rochin Chermat
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Rochin Chermat has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Elena Refet-Mollof
Institut du Génie Biomédical, Polytechnique, Montréal, QC H3T 1J4, Canada
2 shared publications - Philip Wong
Centre de Recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM) Montreal Quebec Canada
2 shared publications - Thomas Gervais
Institute of Biomedical Engineering, Polytechnique Montreal, Montreal, QC H3T 1J4, Canada
2 shared publications David (Run Zhou) Ye
1 shared publicationJean-François Carrier
Centre de recherche du Centre Hospitalier de l'Université de Montréal (CRCHUM), Montreal, Canada
1 shared publicationJulie Lafontaine
1 shared publication
Latest Publications
- Open Access
- 8 September 2026
- Published by Elsevier in SSRN Electronic Journal
Clinically-Relevant On-Chip 3D Hypoxic-Core HyCo Model Shows Impacts on Therapy Resistance and Enables Targeted Drug Validation in Soft-Tissue Sarcoma
Background: Hypoxia influences the biology and response of tumors. Current methods to study hypoxia are low-throughput or use artificial induction, limiting the translational potential of findings. We previously described a user-friendly microfluidic chip to rapidly generate 240 large spheroids naturally harboring a hypoxic core. However, we had yet to validate the clinical relevance of these hypoxic-core (HyCo) spheroids, their use in understanding treatment resistance and their applications in targeted therapy testing. Methods: HyCo and small normoxic spheroids were generated on-chip from commercial and patient-derived soft-tissue sarcoma (STS) cell lines. Presence of hypoxia was validated through in silico modelling, immunofluorescence staining and RTqPCR. Whole-genome RNA sequencing was used to establish HyCo gene expression profile, compared to clinically-derived datasets, and used to identify target genes in hypoxic STSs. Apoptosis staining and clonogenic assay were used to evaluate HyCo therapy resistance to chemotherapy and radiotherapy. Matrigel invasion assay was used to quantify HyCo invasiveness and aggressivity. Diethyl-pythiDC was used to demonstrate the efficacy of P4HA1-inhibition on reducing HyCo invasiveness. Results: Large STSs spheroids generated on-chip naturally exhibit a diffusion-driven hypoxic core in only a few days. These HyCo spheroids recapitulate clinical hallmarks of hypoxia in STS: upregulation of hypoxia-related genes, resistance to chemotherapy/radiotherapy, and increased invasiveness. Our results suggest evidence of treatment resistance driven by hypoxia-induced paracrine signaling in STS. We identified P4HA1 gene as both upregulated in HyCo and prognostic in clinical STS and demonstrated that P4HA1-inhibition using diethyl-pythiDC reduced HyCo invasiveness. Conclusions: Our results demonstrate HyCo spheroids as efficient translational tools to integrate hypoxia in cancer research and drug development. We uncovered evidence of hypoxia-mediated chemoresistance in normoxic regions and successfully identified P4HA1-inhibition as a viable strategy for the treatment of hypoxic STSs, warranting further exploration.
- 8 September 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessClinically-Relevant On-Chip 3D Hypoxic-Core HyCo Model Shows Impacts on Therapy Resistance and Enables Targeted Drug Validation in Soft-Tissue Sarcoma
Background: Hypoxia influences the biology and response of tumors. Current methods to study hypoxia are low-throughput or use artificial induction, limiting the translational potential of findings. We previously described a user-friendly microfluidic chip to rapidly generate 240 large spheroids naturally harboring a hypoxic core. However, we had yet to validate the clinical relevance of these hypoxic-core (HyCo) spheroids, their use in understanding treatment resistance and their applications in targeted therapy testing. Methods: HyCo and small normoxic spheroids were generated on-chip from commercial and patient-derived soft-tissue sarcoma (STS) cell lines. Presence of hypoxia was validated through in silico modelling, immunofluorescence staining and RTqPCR. Whole-genome RNA sequencing was used to establish HyCo gene expression profile, compared to clinically-derived datasets, and used to identify target genes in hypoxic STSs. Apoptosis staining and clonogenic assay were used to evaluate HyCo therapy resistance to chemotherapy and radiotherapy. Matrigel invasion assay was used to quantify HyCo invasiveness and aggressivity. Diethyl-pythiDC was used to demonstrate the efficacy of P4HA1-inhibition on reducing HyCo invasiveness. Results: Large STSs spheroids generated on-chip naturally exhibit a diffusion-driven hypoxic core in only a few days. These HyCo spheroids recapitulate clinical hallmarks of hypoxia in STS: upregulation of hypoxia-related genes, resistance to chemotherapy/radiotherapy, and increased invasiveness. Our results suggest evidence of treatment resistance driven by hypoxia-induced paracrine signaling in STS. We identified P4HA1 gene as both upregulated in HyCo and prognostic in clinical STS and demonstrated that P4HA1-inhibition using diethyl-pythiDC reduced HyCo invasiveness. Conclusions: Our results demonstrate HyCo spheroids as efficient translational tools to integrate hypoxia in cancer research and drug development. We uncovered evidence of hypoxia-mediated chemoresistance in normoxic regions and successfully identified P4HA1-inhibition as a viable strategy for the treatment of hypoxic STSs, warranting further exploration.
- 27 March 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (8) , 2335-2346
Brachytherapy on-a-chip: a clinically-relevant approach for radiotherapy testing in 3d biology
We describe the first microfluidic device for in vitro testing of brachytherapy (BT), with applications in translational cancer research. Our PDMS-made BT-on-chip system allows highly precise manual insertion of clinical BT seeds, reliable dose calculation using standard clinically-used TG-43 formalism and easy culture of naturally hypoxic spheroids in less than 3 days, thereby increasing the translational potential of the device. As the BT-on-chip platform is designed to be versatile, we showcase three different gold-standard post-irradiation bioassays and recapitulate, for the first time on-chip, key clinical observations such as dose rate effect and hypoxia-induced radioresistance. Our results suggest that BT-on-chip can be used to safely and efficiently integrate BT and radiotherapy to translational research and drug development pipelines, without expensive equipment or complex workflows.
- 27 March 2024
- Published by Royal Society of Chemistry (RSC) in Lab on a Chip
- Vol. 24 (8) , 2335-2346
Brachytherapy on-a-chip: a clinically-relevant approach for radiotherapy testing in 3d biology
We describe the first microfluidic device for in vitro testing of brachytherapy (BT), with applications in translational cancer research. Our PDMS-made BT-on-chip system allows highly precise manual insertion of clinical BT seeds, reliable dose calculation using standard clinically-used TG-43 formalism and easy culture of naturally hypoxic spheroids in less than 3 days, thereby increasing the translational potential of the device. As the BT-on-chip platform is designed to be versatile, we showcase three different gold-standard post-irradiation bioassays and recapitulate, for the first time on-chip, key clinical observations such as dose rate effect and hypoxia-induced radioresistance. Our results suggest that BT-on-chip can be used to safely and efficiently integrate BT and radiotherapy to translational research and drug development pipelines, without expensive equipment or complex workflows.